Insider Selling: Agios Pharmaceuticals Inc (NASDAQ:AGIO) Director Sells 3,838 Shares of Stock

Agios Pharmaceuticals Inc (NASDAQ:AGIO) Director Lewis Clayton Jr. Cantley sold 3,838 shares of the stock in a transaction on Thursday, December 7th. The stock was sold at an average price of $59.37, for a total transaction of $227,862.06. Following the sale, the director now directly owns 80,851 shares of the company’s stock, valued at approximately $4,800,123.87. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Lewis Clayton Jr. Cantley also recently made the following trade(s):

  • On Tuesday, November 14th, Lewis Clayton Jr. Cantley sold 4,000 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $60.88, for a total transaction of $243,520.00.
  • On Monday, October 16th, Lewis Clayton Jr. Cantley sold 1,000 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $71.09, for a total transaction of $71,090.00.
  • On Tuesday, October 17th, Lewis Clayton Jr. Cantley sold 4,000 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $71.10, for a total transaction of $284,400.00.
  • On Wednesday, September 13th, Lewis Clayton Jr. Cantley sold 1,000 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $65.47, for a total transaction of $65,470.00.
  • On Thursday, September 14th, Lewis Clayton Jr. Cantley sold 4,000 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $65.59, for a total transaction of $262,360.00.

Shares of Agios Pharmaceuticals Inc (AGIO) traded up $2.66 during trading on Tuesday, hitting $59.83. 409,221 shares of the stock were exchanged, compared to its average volume of 305,841. Agios Pharmaceuticals Inc has a 52-week low of $39.24 and a 52-week high of $72.73. The stock has a market capitalization of $2,920.00, a P/E ratio of -9.54 and a beta of 1.83.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.78) by $0.19. Agios Pharmaceuticals had a negative net margin of 506.39% and a negative return on equity of 69.64%. The company had revenue of $11.35 million for the quarter, compared to analysts’ expectations of $10.85 million. During the same period in the prior year, the business earned ($1.63) earnings per share. Agios Pharmaceuticals’s revenue for the quarter was up 26.4% compared to the same quarter last year. analysts expect that Agios Pharmaceuticals Inc will post -6.59 earnings per share for the current fiscal year.

A number of research analysts have recently issued reports on the stock. Credit Suisse Group boosted their price target on shares of Agios Pharmaceuticals from $61.00 to $66.00 and gave the stock an “outperform” rating in a research report on Thursday, November 2nd. Oppenheimer reiterated a “buy” rating and issued a $83.00 price objective on shares of Agios Pharmaceuticals in a research note on Monday, December 11th. Canaccord Genuity set a $90.00 price target on shares of Agios Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, December 12th. Cann restated a “buy” rating on shares of Agios Pharmaceuticals in a research note on Tuesday, December 5th. Finally, SunTrust Banks set a $80.00 target price on shares of Agios Pharmaceuticals and gave the stock a “buy” rating in a research note on Sunday, November 19th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have assigned a buy rating to the stock. Agios Pharmaceuticals presently has an average rating of “Buy” and an average price target of $75.70.

Several large investors have recently added to or reduced their stakes in AGIO. FMR LLC boosted its stake in shares of Agios Pharmaceuticals by 14.1% during the second quarter. FMR LLC now owns 7,227,331 shares of the biopharmaceutical company’s stock valued at $371,846,000 after purchasing an additional 895,584 shares during the period. Vanguard Group Inc. lifted its stake in Agios Pharmaceuticals by 23.8% in the second quarter. Vanguard Group Inc. now owns 3,214,770 shares of the biopharmaceutical company’s stock worth $165,401,000 after acquiring an additional 617,379 shares during the period. BlackRock Inc. lifted its stake in Agios Pharmaceuticals by 23.5% in the second quarter. BlackRock Inc. now owns 2,675,380 shares of the biopharmaceutical company’s stock worth $137,648,000 after acquiring an additional 508,306 shares during the period. Alkeon Capital Management LLC purchased a new position in Agios Pharmaceuticals during the third quarter valued at $30,489,000. Finally, Janus Henderson Group PLC purchased a new position in Agios Pharmaceuticals during the second quarter valued at $20,423,000. 93.79% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This story was posted by TrueBlueTribune and is owned by of TrueBlueTribune. If you are viewing this story on another publication, it was illegally stolen and republished in violation of U.S. & international trademark & copyright law. The correct version of this story can be viewed at https://www.truebluetribune.com/2018/01/03/agios-pharmaceuticals-inc-agio-director-sells-227862-06-in-stock.html.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Insider Buying and Selling by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply